


**A novel orally bioavailable compound KPT-9274 inhibits
PAK4, and blocks triple negative breast cancer tumor
growth**

Chetan Rane, William Senapedis, Erkan Baloglu,
Yosef Landesman, Marsha Crochiere, Soumyasri
Das-Gupta, Audrey Minden

Supplementary figures




Supplementary Figure 1: iMMECs stably expressing PAK4 were treated with DMSO or KPT-9274, from Day 0 to Day 3. Cells were then incubated with MTT solutions at different time points, followed by measuring absorbance at 560 nm.

i – DMSO (15µM)

ii – KPT-8752 (3µM)

iii – KPT-9274 (1µM)



Supplemental Figure 2: MDA-MB-231 (S1A), MDA-MB-468 (Triple Negative) (S1B) and BT-474 (PR+/HER2+) (S1C) were treated with (i) DMSO (15 µM), or (ii) KPT-8752 (3 µM), or (iii) KPT-9274 (1 µM), for 3 days, following staining for Annexin V / Propidium Iodide (PI).